Based on the Cyclerion Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Cyclerion Therapeutics Inc is not available over the next 12 months. Cyclerion Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Cyclerion Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Cyclerion Therapeutics Inc’s stock price was USD 2.85. Cyclerion Therapeutics Inc’s stock price has changed by +15.38% over the past week, +12.65% over the past month and -15.43% over the last year.
No recent analyst target price found for Cyclerion Therapeutics Inc
No recent average analyst rating found for Cyclerion Therapeutics Inc
Company Overview Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Read Less
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanyla...Read More
Frequently Asked Questions About Cyclerion Therapeutics Inc (CYCN) Stock
Stock Target Advisor's fundamental analysis for Cyclerion Therapeutics Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on CYCN's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CYCN's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on CYCN's stock to indicate if its overvalued.
The last closing price of CYCN's stock was USD 2.85.
The most recent market capitalization for CYCN is USD 6.52M.
Unfortunately we do not have enough analyst data on CYCN's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cyclerion Therapeutics Inc's stock.
As per our most recent records Cyclerion Therapeutics Inc has 1 Employees.
Cyclerion Therapeutics Inc's registered address is 245 First Street, Riverview II, Cambridge, MA, United States, 02142.
You can get more information about it from Cyclerion Therapeutics Inc's website at https://www.cyclerion.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Cyclerion Therapeutics Inc (CYCN) Stock
Stock Target Advisor's fundamental analysis for Cyclerion Therapeutics Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on CYCN's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CYCN's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on CYCN's stock to indicate if its overvalued.
The last closing price of CYCN's stock was USD 2.85.
The most recent market capitalization for CYCN is USD 6.52M.
Unfortunately we do not have enough analyst data on CYCN's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cyclerion Therapeutics Inc's stock.
As per our most recent records Cyclerion Therapeutics Inc has 1 Employees.
Cyclerion Therapeutics Inc's registered address is 245 First Street, Riverview II, Cambridge, MA, United States, 02142.
You can get more information about it from Cyclerion Therapeutics Inc's website at https://www.cyclerion.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CYCN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
